BiotechTube
Atelerix

Atelerix

Newcastle upon Tyne, United Kingdom· Est.
atelerix.co.uk
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $500K

Overview

Atelerix has pioneered a novel cell preservation platform using hypothermic, seaweed-derived hydrogels to maintain biological samples at room temperature. This technology de-risks the supply chain by eliminating dependency on dry ice and complex cold logistics, offering significant cost savings and operational flexibility for research and cell therapy manufacturing. The company has developed a suite of validated, ISO-certified products for specific sample types and has established partnerships with key industry players, positioning itself at the intersection of logistics, sustainability, and advanced therapy enablement.

Biosimilars

Technology Platform

Hypothermic hydrogel encapsulation technology derived from natural biopolymers that stabilizes biological samples (cells, tissues, blood) at ambient temperature without cryopreservation, placing them in a state of suspended animation for transport and storage.

Funding History

1
Total raised:$500K
Grant$500K

Opportunities

The global expansion of cell and gene therapies creates a massive need for reliable, simple logistics for starting materials and final products.
The growing use of complex 3D models (organoids) in drug discovery enables a new distribution model for 'living reagents' shipped assay-ready.
Strong ESG trends favor sustainable technologies that eliminate carbon-intensive cold chain logistics.

Risk Factors

Primary risk is market adoption, requiring a shift from the entrenched standard of cryopreservation.
The company faces potential competition from larger life science tools companies and must scale manufacturing while maintaining impeccable quality.
Growth is dependent on the continued expansion of its target markets like cell therapy and advanced in vitro models.

Competitive Landscape

Atelerix operates in a niche with few direct competitors offering ambient temperature preservation for live cells. It competes indirectly against established cryopreservation protocols, cold chain logistics providers, and specialty media companies. Its key differentiators are product simplicity, room-temperature stability, sustainability, and a validated, ISO-certified platform tailored for specific sample types.

More companies in Biologics / Biosimilars →More companies in United Kingdom →